Patupilone

Drug Profile

Patupilone

Alternative Names: EPO 906; Epothilone B

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Colorectal cancer; Hepatocellular carcinoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Sep 2012 Novartis completes a phase II trial in Prostate cancer (Hormone-refractory, Metastatic disease) in Australia, Belgium, France, Germany, Italy, Singapore, Spain and USA (NCT00411528)
  • 13 Jun 2012 Novartis completes a phase I trial of patupilone in combination with everolimus in Solid tumours (refractory disease) in USA (NCT00496600)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top